Immuno-Oncology Market Size, Share, Trends, Industry Analysis Report By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines), By Novel Target Type, By Tumor or Cancer Type, By Region – Market Forecast, 2025–2034
Description
The Immuno-oncology market size is expected to reach USD 216.34 billion by 2034, according to a new study by Polaris Market Research. The report “Immuno-Oncology Market Share, Size, Trends, Industry Analysis Report By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines), By Novel Target Type, By Tumor or Cancer Type, By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Immuno-oncology can be defined as an advanced therapeutic approach that empowers the body’s immune system to recognize and combat cancer cells with precision. This market is driven by the rapid adoption of combination immunotherapies, which integrate multiple treatment modalities to enhance efficacy, overcome resistance mechanisms, and provide more durable clinical responses. These approaches are gaining traction as they deliver improved patient outcomes compared to monotherapies, supported by ongoing advancements in molecular biology and immune profiling. The increasing success of such combinations is driving research investment and expanding the scope of application across various cancer types, reinforcing their role as a cornerstone of the market’s evolution.
The immuno-oncology market is further influenced by the growing focus on biomarker-driven treatment strategies, enabling the development of highly targeted and personalized therapies. Clinicians can better predict patient response and tailor treatments accordingly by leveraging biomarkers such as genetic mutations, immune signatures, and tumor microenvironment characteristics. This precision-focused approach optimizes therapeutic effectiveness and also minimizes adverse effects, improving overall treatment tolerability. Additionally, the integration of biomarker research into drug development pipelines is accelerating innovation and enabling a shift toward more individualized cancer care solutions within the immuno-oncology landscape.
Immuno-Oncology Market Report Highlights
In terms of treatment approaches, the checkpoint inhibitors led with 57.42% revenue share in 2024, driven by their durable clinical responses across cancers through PD-1/PD-L1 and CTLA-4 targeting.
Based on novel target type, the A2AR antagonist/CD73i therapies segment is expected to register the highest CAGR of 16.1% during the forecast period by disrupting adenosine-mediated immunosuppression in tumors.
In 2024, North America dominated with 31.27% global share, supported by advanced healthcare systems and biopharma innovation hubs.
The Asia Pacific Immuno-Oncology Market would report a CAGR of 16.3% by 2034, fueled by rising treatment access and healthcare investments.
A few global key Immuno-Oncology Market players include Amgen, Inc.; AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; GlaxoSmithKline Plc; Incyte Corporation; Janssen Biotech, Inc; Merck & Co.; Novartis AG; Pfizer Inc.; Roche Holding AG; Sanofi; and Takeda Pharmaceuticals.
Polaris Market Research has segmented the Immuno-Oncology Market report on the basis of treatment approaches, novel target type, tumor or cancer type, and region:
By Treatment Approaches Outlook (Revenue, USD Billion, 2020–2034)
Monoclonal Antibodies
Therapeutic Vaccines
Checkpoint Inhibitors
Cytokines
By Novel Target Type Outlook (Revenue, USD Billion, 2020–2034)
IDO1i
LAG-3 CPI
Oncolytic Virus
STING Agonist
TLR Agonist
HDACi
TIL
VEGFi
MEKi
TIGIT
CPI
GITR Agonist
TGF-b trap
A2AR Antagonist/CD73i
By Tumor or Cancer Type Outlook (Revenue, USD Billion, 2020–2034)
Melanoma
Non-Small Cell Lung Cancer
Renal Cell Carcinoma
Head, Face & Neck Cancer
Bladder Cancer
Classical Hodgkin’s Lymphoma
Merkel Cell Carcinoma
Other Cancer Types
By Regional Outlook (Revenue, USD Billion, 2020–2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Immuno-oncology can be defined as an advanced therapeutic approach that empowers the body’s immune system to recognize and combat cancer cells with precision. This market is driven by the rapid adoption of combination immunotherapies, which integrate multiple treatment modalities to enhance efficacy, overcome resistance mechanisms, and provide more durable clinical responses. These approaches are gaining traction as they deliver improved patient outcomes compared to monotherapies, supported by ongoing advancements in molecular biology and immune profiling. The increasing success of such combinations is driving research investment and expanding the scope of application across various cancer types, reinforcing their role as a cornerstone of the market’s evolution.
The immuno-oncology market is further influenced by the growing focus on biomarker-driven treatment strategies, enabling the development of highly targeted and personalized therapies. Clinicians can better predict patient response and tailor treatments accordingly by leveraging biomarkers such as genetic mutations, immune signatures, and tumor microenvironment characteristics. This precision-focused approach optimizes therapeutic effectiveness and also minimizes adverse effects, improving overall treatment tolerability. Additionally, the integration of biomarker research into drug development pipelines is accelerating innovation and enabling a shift toward more individualized cancer care solutions within the immuno-oncology landscape.
Immuno-Oncology Market Report Highlights
In terms of treatment approaches, the checkpoint inhibitors led with 57.42% revenue share in 2024, driven by their durable clinical responses across cancers through PD-1/PD-L1 and CTLA-4 targeting.
Based on novel target type, the A2AR antagonist/CD73i therapies segment is expected to register the highest CAGR of 16.1% during the forecast period by disrupting adenosine-mediated immunosuppression in tumors.
In 2024, North America dominated with 31.27% global share, supported by advanced healthcare systems and biopharma innovation hubs.
The Asia Pacific Immuno-Oncology Market would report a CAGR of 16.3% by 2034, fueled by rising treatment access and healthcare investments.
A few global key Immuno-Oncology Market players include Amgen, Inc.; AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; GlaxoSmithKline Plc; Incyte Corporation; Janssen Biotech, Inc; Merck & Co.; Novartis AG; Pfizer Inc.; Roche Holding AG; Sanofi; and Takeda Pharmaceuticals.
Polaris Market Research has segmented the Immuno-Oncology Market report on the basis of treatment approaches, novel target type, tumor or cancer type, and region:
By Treatment Approaches Outlook (Revenue, USD Billion, 2020–2034)
Monoclonal Antibodies
Therapeutic Vaccines
Checkpoint Inhibitors
Cytokines
By Novel Target Type Outlook (Revenue, USD Billion, 2020–2034)
IDO1i
LAG-3 CPI
Oncolytic Virus
STING Agonist
TLR Agonist
HDACi
TIL
VEGFi
MEKi
TIGIT
CPI
GITR Agonist
TGF-b trap
A2AR Antagonist/CD73i
By Tumor or Cancer Type Outlook (Revenue, USD Billion, 2020–2034)
Melanoma
Non-Small Cell Lung Cancer
Renal Cell Carcinoma
Head, Face & Neck Cancer
Bladder Cancer
Classical Hodgkin’s Lymphoma
Merkel Cell Carcinoma
Other Cancer Types
By Regional Outlook (Revenue, USD Billion, 2020–2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
128 Pages
- Chapter 1. Introduction
- 1.1 Report Description
- Chapter 2. Research Methodology Overview
- 2.1 Research Process
- 2.1.1 Information procurement
- 2.1.2 Purchased database:
- 2.1.3 Polaris Market Research’s internal database
- 2.2 Research Methodology
- 2.3 Research Scope & Assumptions
- 2.4 List of Data Sources
- Chapter 3. Executive Summary
- 3.1 Market Snapshot - Key Takeaways
- 3.2 Immuno-Oncology (IO) regional market place: Key takeaways
- Chapter 4. Immuno-Oncology (IO) Market Insights
- 4.1 Immuno-Oncology (IO) - Market segmentation & scope
- 4.1.1 Market definitions
- 4.2 Immuno-Oncology (IO) – Market size and growth prospects
- 4.3 Immuno-Oncology (IO) – Value chain analysis
- 4.4 Market Dynamics
- 4.4.1 Drivers
- 4.4.1.1 Increasing introduction of unconventional and advanced treatment techniques
- 4.4.1.2 Rapidly growing population of various cancer infected patients
- 4.4.2 Restraints
- 4.4.2.1 Limited access and awareness about immunotherapy
- 4.4.3 Opportunity analysis: Immunology-oncology market
- 4.4.3.1 Increasing demand for improved cancer care by patients
- 4.5 Porter’s Five Forces Analysis
- 4.6 Immuno-Oncology (IO) – Company Market Share Analysis, 2024
- 4.7 PEST Analysis: Immuno-Oncology Market
- 4.8 Five forces shaping the immuno-oncology market
- 4.9 COVID-19 Impact Analysis
- Chapter 5. Immuno-Oncology Market Estimates and Forecast, by Treatment Approaches
- 5.1 Market size by treatment type
- 5.2 Monoclonal Antibodies
- 5.2.1 Global Immuno-Oncology monoclonal antibodies treatment market estimates & forecasts by region, 2021-2034
- 5.3 Therapeutic Vaccines
- 5.3.1 Global Immuno-Oncology therapeutic vaccines treatment market estimates & forecasts by region, 2021-2034
- 5.4 Checkpoint Inhibitors
- 5.4.1 Global Immuno-Oncology checkpoint inhibitors treatment market estimates & forecasts by region, 2021-2034
- 5.5 Cytokines
- 5.5.1 Global Immuno-Oncology cytokines treatment market estimates & forecasts by region, 2021-2034
- Chapter 6. Immuno-Oncology Market Estimates and Forecast, by Novel Target Type
- 6.1 Market size by novel target type
- 6.2 IDO1i
- 6.2.1 Global Immuno-Oncology market estimates & forecasts for IDO1i target by region, 2021-2034
- 6.3 LAG-3 CPI
- 6.3.1 Global Immuno-Oncology market estimates & forecasts for LAG-3 CPI target by region, 2021-2034
- 6.4 Oncolytic virus
- 6.4.1 Global Immuno-Oncology market estimates & forecasts for Oncolytic virus target by region, 2021-2034
- 6.5 STING agonist
- 6.5.1 Global Immuno-Oncology market estimates & forecasts for STING agonist target by region, 2021-2034
- 6.6 TLR agonist
- 6.6.1 Global Immuno-Oncology market estimates & forecasts for TLR agonist target by region, 2021-2034
- 6.7 HDACi
- 6.7.1 Global Immuno-Oncology market estimates & forecasts for HDACi target by region, 2021-2034
- 6.8 TIL
- 6.8.1 Global Immuno-Oncology market estimates & forecasts for TIL target by region, 2021-2034
- 6.9 VEGFi
- 6.9.1 Global Immuno-Oncology market estimates & forecasts for VEGFi target by region, 2021-2034
- 6.10 MEKi
- 6.10.1 Global Immuno-Oncology market estimates & forecasts for MEKi target by region, 2021-2034
- 6.11 TIGIT
- 6.11.1 Global Immuno-Oncology market estimates & forecasts for TIGIT target by region, 2021-2034
- 6.12 CPI
- 6.12.1 Global Immuno-Oncology market estimates & forecasts for CPI target by region, 2021-2034
- 6.13 GITR agonist
- 6.13.1 Global Immuno-Oncology market estimates & forecasts for GITR agonist target by region, 2021-2034
- 6.14 TGF-b trap
- 6.14.1 Global Immuno-Oncology market estimates & forecasts for TGF-b trap target by region, 2021-2034
- 6.15 A2AR antagonist/CD73i
- 6.15.1 Global Immuno-Oncology market estimates & forecasts for A2AR antagonist/CD73i target by region, 2021-2034
- Chapter 7. Immuno-Oncology Market Estimates and Forecast, by Tumor or Cancer Type
- 7.1 Market size by tumor or cancer type
- 7.2 Melanoma
- 7.2.1 Global Immuno-Oncology market estimates & forecasts for melanoma cancer by region, 2021-2034
- 7.3 Non-small cell lung cancer
- 7.3.1 Global Immuno-Oncology market estimates & forecasts for non-small cell lung cancer by region, 2021-2034
- 7.4 Renal cell carcinoma
- 7.4.1 Global Immuno-Oncology market estimates & forecasts for renal cell carcinoma cancer by region, 2021-2034
- 7.5 Head, face & neck cancer
- 7.5.1 Global Immuno-Oncology market estimates & forecasts for head, face & neck cancer by region, 2021-2034
- 7.6 Bladder cancer
- 7.6.1 Global Immuno-Oncology market estimates & forecasts for bladder cancer by region, 2021-2034
- 7.7 Classical hodgkin’s lymphoma
- 7.7.1 Global Immuno-Oncology market estimates & forecasts for classical hodgkin’s lymphoma cancer by region, 2021-2034
- 7.8 Merkel cell carcinoma
- 7.8.1 Global Immuno-Oncology market estimates & forecasts for merkel cell carcinoma cancer by region, 2021-2034
- 7.9 Other cancer types
- 7.9.1 Global Immuno-Oncology market estimates & forecasts for other cancer types by region, 2021-2034
- Chapter 8. Immuno-Oncology Market Estimates and Forecast, by Region
- 8.1 Market size by region
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 France
- 8.3.2 Germany
- 8.3.3 Italy
- 8.3.4 Spain
- 8.3.5 UK
- 8.3.6 Austria
- 8.3.7 Netherlands
- 8.3.8 Rest of EU
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 Indonesia
- 8.4.5 South Korea
- 8.4.6 Malaysia
- 8.4.7 RoAPAC
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of LATAM
- 8.6 Middle East & Africa
- 8.6.1 Israel
- 8.6.2 Saudi Arabia
- 8.6.3 South Africa
- 8.6.4 UAE
- 8.6.5 Rest of Middle East & Africa
- Chapter 9. Competitive Landscape
- 9.1 Strategy framework
- 9.2 Strategies Adopted By Major Players During COVID-19 Pandemic
- 9.3 Competitive Environment
- 9.4 Merger & Acquisition Analysis
- Chapter 10. Company Profiles
- 10.1 Bristol Myers Squibb
- 10.1.1 Company Overview
- 10.1.2 Financial Performance (Revenue)
- 10.1.3 Product Benchmarking
- 10.1.4 Recent Developments
- 10.2 Merck & Co.
- 10.2.1 Company Overview
- 10.2.2 Financial Performance (Revenue)
- 10.2.3 Product Benchmarking
- 10.2.4 Recent Developments
- 10.3 AstraZeneca
- 10.3.1 Company Overview
- 10.3.2 Financial Performance (Revenue)
- 10.3.3 Product Benchmarking
- 10.3.4 Recent Developments
- 10.4 Roche Holding AG
- 10.4.1 Company Overview
- 10.4.2 Financial Performance (Revenue)
- 10.4.3 Product Benchmarking
- 10.4.4 Recent Developments
- 10.5 Pfizer Inc.
- 10.5.1 Company Overview
- 10.5.2 Financial Performance (Revenue)
- 10.5.3 Product Benchmarking
- 10.5.4 Recent Developments
- 10.6 Incyte Corporation
- 10.6.1 Company Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Benchmarking
- 10.6.4 Recent Developments
- 10.7 Amgen, Inc.
- 10.7.1 Company Overview
- 10.7.2 Financial Performance (Revenue)
- 10.7.3 Product Benchmarking
- 10.7.4 Recent Developments
- 10.8 Eli Lilly and Company
- 10.8.1 Company Overview
- 10.8.2 Financial Performance (Revenue)
- 10.8.3 Product Benchmarking
- 10.8.4 Recent Developments
- 10.9 GlaxoSmithKline Plc
- 10.9.1 Company Overview
- 10.9.2 Financial Performance (Revenue)
- 10.9.3 Product Benchmarking
- 10.9.4 Recent Developments
- 10.10 Janssen Biotech, Inc
- 10.10.1 Company Overview
- 10.10.2 Jonson & Johnson Financial Performance (Revenue)
- 10.10.3 Product Benchmarking
- 10.10.4 Recent Developments
- 10.11 Novartis AG
- 10.11.1 Company Overview
- 10.11.2 Financial Performance (Revenue)
- 10.11.3 Product Benchmarking
- 10.11.4 Recent Developments
- 10.12 Sanofi
- 10.12.1 Company Overview
- 10.12.2 Financial Performance (Revenue)
- 10.12.3 Product Benchmarking
- 10.12.4 Recent Developments
- 10.13 Takeda Pharmaceuticals
- 10.13.1 Company Overview
- 10.13.2 Financial Performance (Revenue)
- 10.13.3 Product Benchmarking
- 10.13.4 Recent Developments
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.